Pioglitazone Increases Serum DPP-4 Level in Type 2 Diabetes MellitusIppei Kanazawa*, Sayuri Tanaka, Masakazu Notsu and Toshitsugu Sugimoto
Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo 693-8501, Japan
- *Corresponding Author:
- Ippei Kanazawa, MD, PhD
Department of Internal Medicine 1
Shimane University Faculty of Medicine
Izumo 693-8501, Japan
E-mail: [email protected]
Received date: July 01, 2014; Accepted date: August 21, 2014; Published date: August 29, 2014
Citation: Kanazawa I, Tanaka S, Notsu M, Sugimoto T (2014) Pioglitazone Increases Serum DPP-4 Level in Type 2 Diabetes Mellitus. J Diabetes Metab 5:416. doi: 10.4172/2155-6156.1000416
Copyright: © 2014 Kanazawa I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Methods: Chronological changes in serum DPP-4 level were observed in 22 patients treated with pioglitazone and 15 with metformin during 12 months. Serum DPP-4 concentrations were measured by an ELISA kit. Results: In the pioglitazone group, serum DPP-4 levels were significantly increased from baseline (774 ± 198 ng/mL) with mean changes of 53 mg/mL [6.8% increase, 95% confidence interval (CI) 2 to 104, p<0.05] after 3 months and of 74 mg/mL (9.4% increase, 95% CI 21 to 126, p<0.01) after 12 months. On the other hand, serum DPP-4 levels were not changed in the metformin group. Percent change in serum DPP-4 level was significantly and positively correlated with percent change in body mass index (r=0.39, p<0.02). The association was still significant even after adjusting for age, duration of diabetes, serum creatinine, and HbAc1 (β=0.59, p<0.02).
Conclusion: The present study showed that pioglitazone, but not metformin, chronologically increased serum DPP-4 levels during 12 months.